Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 10/20 | 0.45 |
| ▸ | PPARG | P37231 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3532628 | 0.87 | KDM1A (0.57) | KDM1APPARAPPARGKDM4EKDR | |
| SCHEMBL5204314 | 0.84 | KDM4E (0.54) | KDM1APPARAPPARGKDM4EKDR | |
| SCHEMBL1436917 | 0.80 | PPARA (0.54) | KDM1APPARAPPARGKDM4E | |
| SCHEMBL5210139 | 0.80 | KDM1A (0.48) | KDM1APPARAPPARGKDM4EKDR | |
| SCHEMBL5208293 | 0.79 | PPARA (0.44) | PPARAPPARG | |
| SCHEMBL4888438 | 0.78 | PPARG (0.57) | KDM1APPARAPPARGKDM4EKDR | |
| SCHEMBL6509332 | 0.78 | PPARG (0.52) | KDM1APPARAPPARGKDM4EKDR | |
| SCHEMBL12617314 | 0.78 | MAPT (0.53) | KDM1APPARAPPARGKDM4ENPC1 | |
| SCHEMBL979145 | 0.77 | KDM4E (0.65) | PPARAPPARGKDM4EKDRHRH3 | |
| SCHEMBL5205865 | 0.77 | KDR (0.40) | PPARAPPARGKDRPRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313717-B1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | LILLY CO ELI (US) | 2007-10-17 | — | — | EP | disclosed |
| US-7176224-B2 | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists | ELI LILLY AND COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-20040138277-A1 | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | ELI LILLY AND COMPANY | 2004-07-15 | — | — | US | disclosed |
| EP-1313717-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016332-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138277-A1 | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | PPARA, PPARD, PPARG | KDM1A 2327/4885PPARA 1/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.